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Table 1. Enzymatic Measurements in the Three Study
Groups, at Diagnosis
Group
A B
82 63
543(164) 539(170)
22(4)
39 (5)
25 (3)
7 (3)
6 (3)
11 11
563(146)
11 (3)C
23 (4)C
25 (5)
12(4)
29 (6)C
0
14
5
290 (160)C
284 (105)C
27
44
129(122)
133(118)
13
39
80 (75)
88(77)
21
241-200
>201
ALT,U/L”
<40
41-200
>201
Total leukocytes/cm3a
Atypicallymphocytes,%
5
25 24
36 34
9 8
53 50
20 5
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No. of patients
Total LD, U/La(N =
100-225 U/L)
LD-1/LD, %
LD-2/LD,%
LD-3/LD %
LD-4/LD, %
LD-5/LD,%
Total LD, U/Lb
300-341
350-499
>500
AST,U/L8(N = 7-40 U/L)
ALT, U/La(N = 7-40 U/L)
AST,U/Li’
<40
3
15
13 889 (1780) 7984 (1074)C
32(2.8) 16 (1.4)c
Mean (and SD).
b No. of patients with each rangeofenzymevalues.
Significantlydifferent from group B (isomorphic increases in all LD isoen-
zymes): P <0.05.
N, normal range.
efficiency of the LD >300 U/L and ALT >41 U/L test
results for determination of IM was better than that of
either the AST >41 U/L or the atypical lymphocytes test
result (100% and 91% vs 78% and 79%, respectively).
The isomorphic pattern has been most frequently de-
scribed in serum of patients with leukemia and lymphoma
(1, 2). The origination of LD in these patients is the
neoplastic B cells (6). Rapidly proliferating cells such as
neoplasticB cellsrequire higher concentrationsof intracel-
lular LD to generate glycolytic energy. In turn, LD is
liberated during the rapid cell turnover. IM is a viral
illness marked by hyperactive B cell proliferation. From
our results, we conclude that the isomorphic LD pattern is
closely correlated to the increased leukocytes count and
specifically to the high percentage of atypical lymphocytes.
Thus, we suggest that in the majority of our patients with
IM, especially in those with the isomorphic pattern, the LD
probably originates from the leukocytes.
LD-5 is the most prominent isoenzyme in tissues with
moreanaerobicmetabolism (e.g., liver, skeletal muscle)(7).
We found a good correlation between AST and ALT values,
which are very sensitive markers for liver disease, and the
increased LD-5 group of patients. Thus in the minority of
our patients with IM, the origin of the LD is the liver, no
doubt attributable to the hepatic parenchymal damage
caused by IM.
We conclude that serum LD, which is a quick, easy,
reliable, and inexpensive laboratory measurement, should
be measured in every patient with clinical suspicion of IM.
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In developing an immunometric assay of intact parathy-
rin (parathyroid hormone, PT!!), we found that affinity
chromatography is a useful tool in purifying and optimiz-
ing the labeling conditions for acridinium ester-labeled
antibodies. We noted this in labeling polyclonal anti-(1-44
PT!!) antibodies with N-hydroxysuccininude acridinium
ester (London Diagnostics, Eden Prairie, MN). The labeled
antibodies were prepared according to published proce-
dures, with 2.5 pg of acridinium ester per 50 pg of antibody
and a reaction time of 15 mm (1).
The labeled antibodies were initially purified by size-
exclusion chromatography on a Sephadex G-25 column, as
described in the literature (1,2). However, we found that
this purified label had relatively low specific binding in the
PTH assay. To test whether a substantial amount of anti-
body had been inactivated or denatured as a result of the
labeling process, we compared the activity of labeled anti-
bodies purified by the Sephadex G-25 column with the
activity of those purified on an affinity column containing
PT!! 1-44 immobilized on cyanogen bromide-activated
Sepharose 4B. A 0.7 cm (i.d.) x 4 cm affinity column was
used with an application buffer of pH 7.4 phosphatebuffer,
0.10 moIIL, containing 1 g of bovine serum albumin, 1 mL
of Triton X-100, 9 g of sodiumchloride, and 0.2 g of sodium
azide per liter. Nonretained components were washed from
the affinity column with a pH 5.0 phosphate buffer, 0.10
moIIL, and the retained antibodies were eluted in pH 2.3
HC1 or pH 2.3 glycine buffer, 0.10 mol/L, containing 1 mL
of Triton X-100 and 9 g of sodium chloride per liter.
The labeled antibodies purified by the affinity and Seph-
adex G-25 columns were compared by using equal counts of
each in the assay of intact PTH. The calibration curves
obtained are shown in Figure 1. Both types of labeled
antibodies had similar background counts, but the response
C,
‘O
*
U)
C
0
0
125
100
75
50
25
0
0 25 50 75 100
118 CLINICAL CHEMISTRY, Vol. 37, No. 1, 1991
PTH conc, pmol/L
Fig. 1. CalIbrationcurves for an intact PTH immunometricassay
invoMng acridinium ester-labeled antibodies purified byaffinitychro-
matography(U) or by a SephadexG-25 column(#{149})
obtained with the label purified by the Sephadex G-25
column was only half that of the affinity-purified label. To
examine the reason for this, we applied to the affinity
column a portion of the Sephadex G-25-purified label.
Protein assaysand chemiluminescentmeasurementsofthe
retained and nonretained fractions revealed that >50% of
these labeled antibodies could not bind to the immobilized
PTH fragments.
We also used the affinity column to monitor the produc-
tion of active labeled antibodies; decreasing the amount of
acridinium ester dramatically improved the amount of
active labeled antibodies obtained. When 2.5 pg of acridi-
mum ester per 50 pg of antibody was used, 72% of the
chemiluininescent species in the reaction mixture was
eluted without binding to the affinity column. At 0.625-
1.25 pg of acridinium ester per 50 pg of antibody, this was
reduced to 30%, with the remainder of the counts appearing
in the active antibody fraction. The labeling reaction time
was less crucial. For example, at 1.25 pg of acridinium
ester per 50 pg of antibody, there was no apparent decrease
in the relative amount of active labeled antibodies over
reaction times of 5-15 mm. Indeed, the actual time re-
quired for labeling could be very short, with the reaction
being almost 75% complete in only 5 mm.
In summary, affinity chromatography was found to be
useful in the purification of acridinium ester-labeled anti-
bodies, particularly for removing denatured antibodies
from the prepared label and for monitoring the amount of
active labeled antibodies produced.
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